Study Finds Surprising Trend Among Ozempic Users Taking Fewer Doses Than Usual
Gizmodo • • general
Key Points:
- Researchers at Scripps Health found that patients who reduced their dosing frequency of GLP-1 treatments like semaglutide generally maintained weight loss and improved health markers, even with doses as infrequent as once every two months.
- The study, involving 30 participants on reduced doses of tirzepatide or semaglutide, showed most patients maintained stable BMI, blood pressure, cholesterol, and blood sugar levels over an average follow-up of 36 weeks.
- GLP-1 medications, while effective for weight loss, have drawbacks such as gastrointestinal side effects and high costs, making long-term use challenging for many patients.
- Although promising, the findings are preliminary due to the small sample size, and larger randomized controlled
